Cymbalta Liver Safety Was Key Review Issue Delaying Lilly’s Antidepressant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Initial approval of Lilly’s Cymbalta appears to have been delayed primarily by concerns over liver toxicity, FDA review documents for the serotonin-norepinephrine reuptake inhibitor show.
You may also be interested in...
Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta
Review documents for Cymbalta note a difference in opinion regarding the significance of drug interactions between FDA’s review divisions for the two duloxetine indications – major depressive disorder and stress urinary incontinence (under the trade name Yentreve).
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011